Denmark

Denmark is a tightly controlled but scientifically credible psychedelic research country. It has no adult-use, decriminalised or ceremonial pathway, and classical psychedelics remain limited to authorised research or special permission.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Denmark.

1
Denmark is a research-and-specialist-care jurisdiction, not a broad psychedelic access market.
2
Classical psychedelics remain controlled: LSD is List A, while psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine and ketamine are List B substances.
3
Esketamine is the only clearly authorised psychiatric medicine in this field, with a November 2025 Medicinraadet recommendation for a defined treatment-resistant depression subgroup.
4
Copenhagen is the centre of gravity, with Rigshospitalet, Bispebjerg and Frederiksberg Hospital, Psychiatric Centre Copenhagen and the University of Copenhagen carrying most visible clinical research.
5
Denmark has distinctive psilocybin work in alcohol use disorder and chronic cluster headache, plus LSD receptor-occupancy imaging.
6
The main near-term watch item is evidence output from the Copenhagen alcohol programme and PsyPal, not a sudden legal opening.

Research Snapshot

Blossom currently tracks 12 psychedelic clinical trials connected to Denmark, including 7 active studies.

Active trials: 7
Total trials: 12
Stakeholders: 10
Events: 0

Top Compounds

Psilocybin(8)
Esketamine(2)
Ketamine(1)
LSD(1)

Active Trial Preview

View all trials →

Medical Access Snapshot

Denmark does not offer routine medical access to classical psychedelics. Psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine and related substances remain controlled and are accessible only through authorised research or special permissions. Esketamine is the meaningful current access route: Medicinraadet now recommends Spravato for a defined treatment-resistant depression subgroup and for acute suicidal-risk care, but treatment remains specialist and supervised.

View trials→View stakeholders→Open access guide→

Regulatory Status

Denmark remains tightly controlled for classical psychedelics. LSD is on List A, while psilocybin, psilocin, psilocybin-containing mushrooms and spores, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine and ketamine are controlled on List B. List A substances must not be present in Denmark unless the Danish Medicines Agency gives special permission; List B substances may be used only for medical and scientific purposes. Private individuals may possess controlled substances only where prescribed as medicinal products. Current routine care is therefore not a psilocybin, LSD or MDMA access story. Esketamine is the clear authorised psychiatric route, and Medicinraadet now recommends it for a defined treatment-resistant depression subgroup as well as acute suicidal-risk care.

History of Research in Denmark

Denmark has a deeper psychedelic history than many small European countries. From 1960 to 1973, Frederiksberg Hospital in Copenhagen treated hundreds of psychiatric patients with LSD and, in some cases, psilocybin. Later historical work has made this pre-prohibition record unusually visible. # #

That history is also why Danish debate is cautious. The early LSD treatment era produced later complaints and compensation claims, and Denmark enacted an LSD damages law in 1986. Current archival papers therefore read the period as both a research legacy and a warning about weak safeguards. # #

The modern restart has been institution-led. Denmark returned to psychedelic science through hospital psychiatry, neuroimaging and investigator-led trials rather than private clinics. The Danish Medicines Agency remains central because controlled-substance permissions and clinical-trial authorisations sit inside standard medicines regulation. # # #

By 2024-2026, the modern Danish profile had become clearer: psilocybin studies in alcohol use disorder and cluster headache, LSD receptor-occupancy imaging at Rigshospitalet, Danish participation in COMPASS studies, and a foothold in the EU-funded PsyPal palliative-care trial. # # # # #

Copenhagen

Copenhagen is the obvious Danish hub. It combines the medicines regulator, university hospitals, University of Copenhagen infrastructure and the main visible psychedelic research groups. That concentration is why Denmark matters internationally despite its small size. # # # #

Psychiatric Centre Copenhagen, Bispebjerg and Frederiksberg Hospital, and the University of Copenhagen are central to the alcohol-use-disorder work, including the Quantum Trip Trial. # # #

Rigshospitalet's Neurobiology Research Unit anchors the imaging and pharmacology side, including the chronic cluster-headache psilocybin work and the dOccLS LSD receptor-occupancy programme. # #

Aarhus and University of Southern Denmark matter more as secondary research nodes. Aarhus is visible in social-science and policy work on psychedelic self-care, while University of Southern Denmark contributes preclinical psilocin and pharmacology research. # #

Research Focus

Alcohol use disorder is Denmark's standout therapeutic focus. A Copenhagen open-label study of single-dose psilocybin therapy was published in 2025, and the larger Quantum Trip Trial was designed as a randomised, double-blind, placebo-controlled study in treatment-seeking adults. Its February 2026 statistical analysis plan recorded 59 enrolled participants, 51 primary-endpoint completers and follow-up due to finish by the end of March 2026. # # #

Headache medicine is a second Danish niche. The 2024 chronic cluster-headache paper reported a small open-label psilocybin study in 10 patients and linked clinical change to hypothalamic functional-connectivity measures. The sample is small, so this is an early signal rather than a basis for routine care. #

Mechanistic neuroscience is the third strength. Rigshospitalet's Neurobiology Research Unit runs the dOccLS programme on LSD occupancy at the 5-HT2A receptor in the living human brain, and Denmark contributed participants to COMPASS Pathways' Phase IIb psilocybin treatment-resistant depression study. # #

Denmark is also part of PsyPal, the EU-funded psilocybin trial in non-oncology palliative care, with University of Copenhagen reporting first-patient inclusion in 2025. Outside Copenhagen, Aarhus University contributes social-science and policy work, while University of Southern Denmark adds preclinical psychedelic pharmacology. # # # #

Key Milestones

1960-1973

Frederiksberg Hospital in Copenhagen treats psychiatric patients with LSD and some psilocybin, making Denmark a major Scandinavian site of early psychedelic psychiatry.

1986

Denmark enacts the LSD damages law, creating a compensation route for alleged long-term harm from earlier LSD treatments.

2019

Spravato receives EU marketing authorisation, creating the main authorised psychedelic-adjacent psychiatric medicine relevant to Denmark.

2019

Denmark authorises the local psilocybin study in chronic cluster headache.

2021

COMPASS Pathways' Phase IIb psilocybin trial ends globally, with Danish participant contribution recorded in the trial results.

2023

Medicinraadet recommends esketamine as a possible standard treatment for adults admitted with unipolar depression and acute suicidal risk.

2024

Danish chronic cluster-headache psilocybin results are published in Headache.

2025

Denmark publishes an open-label psilocybin alcohol-use-disorder study, while recruitment in the Quantum Trip Trial ends.

20 Nov 2025

Medicinraadet announces that it now recommends esketamine for adults with moderate-to-severe treatment-resistant depression after at least three failed antidepressant treatments.

Future Outlook

The most likely near-term change is publication flow. The Copenhagen alcohol-use-disorder programme has the clearest pending Danish clinical read-out, and PsyPal should become more visible as recruitment and follow-up mature across participating countries. # # #

Access change is more likely to happen through esketamine implementation than through psilocybin or MDMA. Medicinraadet has now recommended esketamine for a defined treatment-resistant depression subgroup, but the pathway still depends on hospital visits, start-stop criteria, monitoring and regional delivery capacity. # # #

For classical psychedelics, the separation between evidence generation, authorisation and reimbursed care remains strong. Denmark has the scientific infrastructure to run sophisticated trials, but no official source reviewed here indicates imminent routine medical access to psilocybin, LSD or MDMA outside trials. # # #